Updated: August 13, 2026 | 12-minute read
Light absorption in red light therapy is often described too simply. Photons do not travel through tissue in straight, uniform paths, and a wavelength does not automatically correspond to one fixed treatment depth or one guaranteed biological effect. Reflection, scattering, absorption, tissue composition, beam geometry, skin pigmentation, treatment distance, irradiance, exposure time, and device stability all influence the optical dose that reaches tissue.
At the cellular level, cytochrome c oxidase (CCO) is a leading proposed photoacceptor for red and near-infrared photobiomodulation (PBM), but it is not the only possible pathway. Hemoglobin, melanin, water, lipids, opsins, ion channels, and other cellular structures can also influence light transport or biological signaling. Therefore, the most accurate way to evaluate a red light therapy device is to connect its measured optical output to a complete, evidence-relevant protocol—not to assume that wavelength or wattage alone guarantees a result.
This article explains what light absorption means, how wavelength affects tissue propagation, why Beer–Lambert is only a simplified starting point for biological tissue, and what quality systems, safety reports, FDA status, and model-specific optical testing can—and cannot—prove.
What light absorption actually means in red light therapy
Photons from LED panel entering skin layers with chromophore absorption zones highlighted
In physics, absorption occurs when matter takes up photon energy. In biological tissue, however, incoming light can be reflected, scattered, transmitted, or absorbed. Scattering changes a photon's direction and effective path length, while absorption transfers energy to a molecule or structure. The balance among these processes depends on wavelength and tissue composition.
Photon energy follows:
E = hf = hc/λ
where E is photon energy, h is Planck's constant, f is frequency, c is the speed of light, and λ is wavelength. A 660 nm photon therefore carries more energy than an 850 nm photon. That difference matters, but photon energy alone does not determine treatment depth or biological response. Tissue absorption coefficients, scattering coefficients, anisotropy, beam width, irradiance, exposure time, and anatomy must also be considered.
Karu's early work helped establish the idea that cellular responses to red and near-infrared light depend on photon absorption by endogenous photoacceptors. Subsequent research has supported an important role for mitochondrial signaling, while also identifying mechanisms beyond CCO. It is therefore more accurate to say that absorption is necessary to initiate a photochemical interaction, not that every absorbed photon produces a therapeutic response or that every unabsorbed photon is irrelevant. A photon may be absorbed by a competing tissue absorber, reach another cell, scatter away from the target, or leave the tissue entirely.
For device evaluation, this distinction matters. A specification such as 660 nm or 850 nm describes the optical source, but it does not by itself show how much energy reaches a target tissue or whether the resulting dose matches a validated clinical protocol.
The main absorbers and proposed photoacceptors
Skin cross-section showing cytochrome c oxidase, hemoglobin, water, and melanin absorption targets
Several endogenous substances influence red and near-infrared light in tissue:
- Melanin is a broad-spectrum absorber concentrated mainly in the epidermis. Its absorption generally decreases as wavelength increases through the visible and near-infrared range.
- Oxyhemoglobin and deoxyhemoglobin absorb light in blood. Their wavelength-dependent spectra strongly influence how much light remains available beyond superficial and vascular layers.
- Water is present throughout tissue. Its absorption is relatively low in parts of the red and near-infrared optical window but rises at longer infrared wavelengths, with important spectral features near and above approximately 970 nm.
- Lipids and other tissue components also contribute to absorption and scattering.
- Cytochrome c oxidase, located in the inner mitochondrial membrane, is a leading proposed intracellular photoacceptor for parts of the red and near-infrared spectrum.
- Other proposed pathways, including opsins, light-sensitive ion channels, interfacial water, nitric-oxide-related signaling, and secondary mitochondrial redox responses, remain active areas of research.
It is important not to describe melanin, hemoglobin, water, and CCO as four equivalent "therapeutic targets." Melanin, hemoglobin, and water are major determinants of tissue optics and may act as competing absorbers. CCO and other cellular structures are discussed as possible initiators of PBM signaling. These roles overlap, but they are not identical.
The tissue optical window is also not one universally fixed range. Depending on the tissue, measurement method, and application, literature may describe useful transmission windows extending from roughly 600 nm into the near-infrared. Within these windows, absorption by some major tissue chromophores is comparatively lower, but scattering remains substantial.
Skin pigmentation affects optical transmission. Studies report that darker skin can have higher absorption over portions of the 400–1000 nm range. However, this does not justify a universal rule to increase irradiance or treatment time for darker skin. Higher surface absorption may also change heating and safety margins. Protocols should be validated across representative skin tones rather than automatically adjusted using an unverified multiplier.
How wavelength affects tissue penetration
Side-by-side depth penetration diagram for 630 nm, 660 nm, and 850 nm wavelengths through layered tissue
Under comparable conditions, red wavelengths around 630–670 nm are generally used for relatively superficial targets, while near-infrared wavelengths around 810–850 nm often retain more relative intensity at greater tissue depth. This is a useful design principle, but it is not a precise anatomical map.
Statements such as "660 nm penetrates 1–3 mm" or "850 nm penetrates several centimeters into a joint" can be misleading unless they define:
- the tissue and anatomical site;
- whether the result is measured or simulated;
- the definition of penetration depth, such as 1/e, 10%, or 1% of a reference value;
- the incident beam diameter and geometry;
- skin pigmentation and tissue composition;
- whether the reported value represents detectable light or a biologically validated dose.
Detecting a small amount of light at a particular depth is not the same as delivering a clinically effective radiant exposure there. Optical penetration depth, maximum detectable depth, and therapeutic depth are different concepts.
Product examples without overinterpreting wavelength
The EST-T1 desktop panel is specified with 660 nm and 850 nm channels in a 1:1 LED-count ratio and approximately 35 mW/cm² at 15 cm. The two wavelengths provide a mixed red and near-infrared spectrum, but "1:1" should not automatically be interpreted as equal optical power or equal dose at every tissue depth. Buyers should confirm whether a wavelength ratio refers to LED count, emitting dies, electrical power, radiant power, or measured irradiance.
The physically correct selection order is therefore:
- Define the intended use and target area.
- Identify evidence-relevant wavelength and protocol parameters.
- Verify measured output and uniformity at the actual treatment distance.
- Calculate surface radiant exposure without treating it as the unknown deep-tissue dose.
- Check model-specific safety and regulatory documentation.
Beer–Lambert law, scattering, and treatment distance
Irradiance-distance curve and Beer-Lambert attenuation overlay through tissue layers
The standard Beer–Lambert expression is often written as:
I = I₀e^(−μx)
where I₀ is incident intensity, I is the intensity after path length x, and μ is an attenuation term. This expression is useful for explaining exponential loss in a simple, homogeneous medium. Biological tissue, however, is heterogeneous and strongly scattering. A single absorption coefficient cannot fully describe photon transport through layered skin, fat, muscle, blood, and connective tissue.
For tissue applications, researchers may use an effective attenuation coefficient, the modified Beer–Lambert law, diffusion theory, adding-doubling methods, or Monte Carlo radiative transport. These approaches account for scattering and path-length effects more realistically. Even then, model outputs depend on their optical-property inputs and assumptions.
Distance in air
Over ordinary panel working distances, absorption by air is usually negligible. The important changes before light reaches the skin are geometric spreading, lens divergence, LED-beam overlap, panel dimensions, and detector position.
The inverse-square law is valid for an ideal point source or an extended source measured sufficiently far away to satisfy a far-field approximation. A large LED panel used at 15–30 cm is often in the near field, so doubling distance does not necessarily reduce irradiance to exactly one quarter. The correct approach is to measure the actual device at each relevant distance.
Surface dose
Surface radiant exposure can be calculated as:
Radiant exposure (J/cm²) = irradiance (mW/cm²) × time (seconds) ÷ 1000
For example, 35 mW/cm² applied for 600 seconds equals 21 J/cm² at the measurement plane. This calculation does not tell us the dose absorbed by CCO or delivered to a deep muscle or joint. It also does not establish that 21 J/cm² is appropriate for a particular condition.
Beam angle and housing design
A narrower lens may concentrate output over a smaller field, while a wider lens may improve overlap across a larger area. Neither automatically provides better therapy. A multi-point irradiance map should be used to evaluate peak output, area average, minimum, maximum, and uniformity at the working distance.
Housing design also matters. LED spacing, lenses, heat sinking, ventilation, drivers, and panel depth can affect temperature, spectrum, output stability, and uniformity. These variables should be verified by thermal, spectral, electrical, and optical testing rather than inferred from appearance.
Why wavelength accuracy and irradiance stability matter
Measured wavelength spectrum versus undocumented or unstable device output
Wavelength accuracy matters, but narrow "correct versus wrong wavelength" claims should be avoided. PBM action spectra reported in the literature include multiple peaks and bands, and common LEDs have a finite spectral bandwidth. Research has reported cellular responses around both 660–670 nm and approximately 680 nm under specific experimental conditions. Therefore, a device emitting at 680 nm should not automatically be described as biologically inactive simply because its label was expected to say 660 nm.
For procurement and quality control, the useful questions are:
- What is the measured peak wavelength?
- What is the production tolerance?
- What is the full width at half maximum (FWHM)?
- Was the spectrum measured at cold start or after thermal stabilization?
- How much does peak wavelength and optical output change during operation?
- Are red and NIR channels measured separately and simultaneously?
- Does the report cover the exact model and configuration being purchased?
Irradiance data require similar context. A single centre-point reading may overstate the average exposure across a large treatment field. A credible report should identify the distance, instrument, calibration status, warm-up time, sensor orientation, channel settings, grid, peak value, average value, and uniformity.
What quality systems, safety standards, and FDA status actually prove
Quality systems and regulatory documents serve different purposes. They should not be presented as interchangeable proof of wavelength accuracy, clinical effectiveness, or market authorization.
ISO 13485
ISO 13485:2016 specifies requirements for a medical-device quality management system. Within the certified organization's stated scope, it supports controlled design and production processes, supplier management, calibration, documentation, traceability, corrective action, and other quality-system activities.
It does not, by itself, prove that every model emits a particular wavelength, achieves a stated irradiance, or produces a clinical benefit. Those claims require model-specific design records and test evidence.
REDDOT LED applies its ISO 13485 quality system together with a 37-step quality inspection process. That process can support repeatable manufacturing when the individual inspection steps, acceptance criteria, equipment, sampling plan, records, and change controls are documented. The "37-step" statement should remain consistent across the company website and supporting materials.
IEC 62471
IEC 62471 provides a framework for evaluating photobiological hazards from lamps and lamp systems, including LEDs. A model-specific report may support assessment of retinal and skin exposure hazards and risk classification under stated test conditions.
IEC 62471 does not prove clinical effectiveness, tissue penetration, CCO activation, or accuracy of every treatment claim. The report should be checked for the exact model, spectrum, operating mode, measurement distance, exposure duration, and risk group.
ETL listing
An ETL Listed mark indicates that a specific product has been tested and certified to the applicable North American product-safety standard identified in its listing. It can support electrical and product-safety compliance within that scope and is normally associated with ongoing factory surveillance.
ETL listing should not be described as proof of therapeutic wavelength accuracy, PBM efficacy, or FDA labeling review unless the underlying report explicitly includes a separate performance evaluation addressing those parameters.
FDA establishment registration and device listing
FDA establishment registration and device listing identify regulated establishments and listed device activities. FDA expressly states that registration or listing does not denote approval, clearance, certification, or authorization of the establishment or its products.
REDDOT LED's establishment registration number can be reported as a traceable registration fact, but it should not be used as evidence that FDA reviewed the optical output or clinical claims of every REDDOT model.
510(k)-exempt products
Some red or infrared light products may fall within an FDA classification that is exempt from premarket notification under section 510(k). For example, the FDA classification database identifies certain infrared therapeutic heating lamps under 21 CFR 890.5500 as Class II and 510(k)-exempt. Other PBM devices, intended uses, or product codes may require a 510(k) submission.
Therefore, it is accurate to state that some REDDOT LED product configurations may qualify for a 510(k)-exempt pathway when the exact model, product code, intended use, listing, and limitations of exemption support that status.
When making an exemption statement, provide:
- the legal manufacturer;
- the exact model or device family;
- the FDA product code and regulation number;
- the device listing where applicable;
- the intended use and claims;
- confirmation that the device does not exceed the limitations of exemption.
If a product's intended use or marketing claims move beyond the exempt classification, a different regulatory pathway may apply.
CE marking and other documents
CE marking indicates that the manufacturer declares conformity with the applicable European Union requirements after following the relevant conformity-assessment route. Depending on the product and classification, notified-body involvement may or may not be required. CE marking is not automatically a third-party "certificate," nor is it universal proof of medical effectiveness.
FCC documentation addresses radio-frequency emissions or radio functions within its applicable scope. RoHS addresses specified restricted substances. Neither proves therapeutic effectiveness. Every document should be matched to the exact legal entity, manufacturing site, model, standard, intended use, and destination market.
From photon exposure to a possible cellular response
Flowchart of photon to ATP cellular response with evidence and compliance checkpoints annotated
A more accurate PBM pathway is conditional rather than guaranteed:
- An LED emits a spectrum with a measurable peak, bandwidth, output, and waveform.
- The optical field changes with distance, lenses, beam overlap, temperature, and panel geometry.
- At the tissue surface, some light is reflected while the remainder is scattered, transmitted, or absorbed.
- Absorption by tissue chromophores and proposed cellular photoacceptors may initiate photochemical and redox events.
- Depending on wavelength, dose, cellular state, and protocol, studies report possible modulation of mitochondrial activity, ATP, reactive oxygen species, nitric oxide, calcium signaling, and transcription factors.
- Whether these changes translate into a meaningful clinical outcome depends on the indication, protocol, population, comparator, and quality of evidence.
This pathway explains why no single certificate "closes the physics loop." Optical performance reports verify output. IEC 62471 addresses photobiological hazards. ETL may address applicable product-safety standards. ISO 13485 addresses the quality management system. FDA registration, listing, exemption, clearance, or approval each has a distinct regulatory meaning. Clinical evidence evaluates health outcomes. One document cannot substitute for all the others.
Key takeaways
- CCO is a leading proposed PBM photoacceptor, not the only established pathway.
- Melanin, hemoglobin, water, and lipids influence tissue optics but should not all be described as equivalent therapeutic targets.
- 630–670 nm red light is generally associated with more superficial propagation, while 810–850 nm NIR often retains more relative intensity at depth under comparable conditions; neither wavelength defines an exact anatomical treatment depth.
- Beer–Lambert is a useful simplified concept, but strongly scattering, layered tissue requires more advanced models for quantitative predictions.
- The inverse-square law should not be used automatically for a large LED panel at short working distances. Request measured multi-distance data.
- Surface radiant exposure is not the same as absorbed dose at a deep chromophore.
- A 20 nm spectral difference does not automatically make a device ineffective; evaluate peak wavelength, FWHM, tolerance, temperature, and the relevant protocol.
- ISO 13485, IEC 62471, ETL, FDA status, CE, FCC, and optical test reports support different claims and must not be treated as interchangeable.
- Some products may be 510(k)-exempt, but exemption must be confirmed for the exact classification, model, intended use, and limitations of exemption.
- REDDOT LED's 37-step quality inspection process should be described as a manufacturing control system, not as clinical proof.
FAQ
Is there actual science behind red light therapy?
Yes. Peer-reviewed research supports photochemical and cellular effects of red and near-infrared light under defined conditions. CCO-related mitochondrial signaling is one leading mechanism, while other pathways are also under investigation. Clinical evidence is indication-specific and highly dependent on wavelength, irradiance, radiant exposure, treatment schedule, tissue, and study design. Mechanistic evidence does not mean every consumer device or health claim is clinically proven.
What does Mayo Clinic say about red light therapy?
A Mayo Clinic dermatologist has discussed red light as an option sometimes used for acne and photoaging. That should not be expanded into a blanket Mayo Clinic endorsement for psoriasis, wound healing, pain, or every red-light application. "Light therapy" can also refer to ultraviolet phototherapy, blue light, photodynamic therapy, or intense pulsed light, which should not be conflated with red/NIR photobiomodulation.
Can red light therapy regrow gums?
"Regrow gums" is stronger than current evidence supports. PBM has been studied in dentistry and periodontology as an adjunct to standard care, with some studies reporting effects on pain, inflammation, or healing-related outcomes. It should not be presented as a replacement for periodontal diagnosis, scaling and root planing, surgery, or other indicated treatment. Any claim should be tied to a specific systematic review, wavelength, dose, and procedure.
Why isn't photobiomodulation routinely recommended for every condition?
Evidence quality and protocol standardization vary substantially by indication. Studies use different wavelengths, irradiances, radiant exposures, pulse modes, treatment areas, schedules, and outcome measures. Product regulatory status and permitted claims also vary. Some clinicians use PBM for defined applications, while others wait for stronger product- and protocol-specific evidence. This is different from saying that the underlying physics is invalid.
What should buyers request from a red light therapy manufacturer?
Request the exact model's spectrum, wavelength tolerance, FWHM, multi-distance irradiance data, area-uniformity map, waveform or pulse report where relevant, instrument and calibration details, warm-up and thermal-stability data, IEC 62471 assessment, applicable electrical and EMC reports, regulatory status for the destination market, quality-system certificate scope, warranty terms, and production change-control process.
References
- Karu TI. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. Journal of Photochemistry and Photobiology B. 1999;49(1):1–17. https://pubmed.ncbi.nlm.nih.gov/10365442/
- Karu TI. Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochemistry and Photobiology. 2008;84(5):1091–1099. https://pubmed.ncbi.nlm.nih.gov/18651871/
- Wong-Riley MTT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. Journal of Biological Chemistry. 2005;280(6):4761–4771. https://pubmed.ncbi.nlm.nih.gov/15557336/
- Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017;4(3):337–361. https://pubmed.ncbi.nlm.nih.gov/28748217/
- Hamblin MR. Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochemistry and Photobiology. 2018;94(2):199–212. https://pmc.ncbi.nlm.nih.gov/articles/PMC5844808/
- Mayo Clinic News Network. Dermatologist Explains Light Therapy for Skin. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-minute-dermatologist-explains-light-therapy-for-skin/
- Zein R, Selting W, Hamblin MR. Review of light parameters and photobiomodulation efficacy: dive into complexity. Journal of Biomedical Optics. 2018;23(12):120901. https://pubmed.ncbi.nlm.nih.gov/30550048/
- Ash C, Dubec M, Donne K, Bashford T. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. Lasers in Medical Science. 2017;32(8):1909–1918. https://pmc.ncbi.nlm.nih.gov/articles/PMC5653719/
- Finlayson L, et al. Depth penetration of light into skin as a function of wavelength from 200 to 1000 nm. Photochemistry and Photobiology. 2022;98(4):974–981. https://pubmed.ncbi.nlm.nih.gov/34699624/
- Setchfield K, et al. Effect of skin color on optical properties and the implications for medical optical technologies: a review. Journal of Biomedical Optics. 2024;29(1):010901. https://pmc.ncbi.nlm.nih.gov/articles/PMC10807857/
- Moreno I, Sun CC, Ivanov R. Far-field condition for light-emitting diode arrays. Applied Optics. 2009;48(6):1190–1197. https://pubmed.ncbi.nlm.nih.gov/23567581/
- International Organization for Standardization. ISO 13485:2016—Medical devices—Quality management systems. https://www.iso.org/standard/59752.html
- International Electrotechnical Commission. IEC 62471:2006—Photobiological safety of lamps and lamp systems. https://webstore.iec.ch/en/publication/7076
- U.S. Food and Drug Administration. Important Reminders about Registration and Listing. https://www.fda.gov/medical-devices/device-registration-and-listing/important-reminders-about-registration-and-listing
- U.S. Food and Drug Administration. Class I and Class II Device Exemptions. https://www.fda.gov/medical-devices/classify-your-medical-device/class-i-and-class-ii-device-exemptions
- U.S. Food and Drug Administration. Product Classification—Infrared Lamp, 21 CFR 890.5500, product code ILY. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=ILY
- U.S. Food and Drug Administration. Photobiomodulation Devices—Premarket Notification [510(k)] Submissions, Draft Guidance. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions
- Intertek. ETL Listed Mark—Product Certification. https://www.intertek.com/product-certification-marks/etl/
- European Union. CE Marking—EU Requirements. https://europa.eu/youreurope/business/product-rules-compliance/general-product-compliance/ce-marking/index_en.htm